Spinal cord injury (SCI) patients are at high risk of developing cystitis, and vesical neoplasia, As abnormal growth regulation of urothelium may be a predisposing factor for cystitis and vesical neoplasia, we studied alterations if any, in the expression and localization of epidermal growth factor receptor (EG RF) in the vesical urothelium by an immuno-histochemical technique, using monoclonal mouse anti-human epidermal growth factor receptor antibody (DAKO-EGFRl) in cold-cup biopsies taken from the trigone of the urinary bladder in 18 adult SCI patients who had a neuropathic bladder. Abnormal localisation of EGFR-p, i.e. cytoplasmic, was noted in 13 patients. A linear localization of EG FR-p along the cell membrane of the urothelium, considered as an essential requirement for effective function, was observed in only three cases. Combined cytoplasmic and cell membrane location of EGFR-p was seen in two patients. The three patients with cell membrane location of EGFR-p showed a strong expression of EGFR-p (2 +-, 2 -3 +, and 4 +-, respectively); the intensity of EGFR-p expression in cases of cytoplasmic immunostaining varied considerably. Histopathology revealed denuding cystitis in one; follicular cystitis in four; active inflammatory infiltrate in three; lymphocytic infiltrate in three; squamous metaplasia in six; and intestinal metaplasia in three biopsy specimens.
Introduction
Growth factors are relatively small proteins that interact with cells to regulate cell biology. Cellular processes responsive to trophic factors are myriad but include such fundamental issues as proliferation, differentiation, adhesion, motility, peri-cellular proteo lysis, and extracellular matrix production. 1 Ultimately, growth factors influence cell biology by regulating gene expression. For a given growth factor, changes in concentration, surface receptor number, type, occu pancy, and second messenger signal transduction are important determinants of both the nature and magnitude of downstream events. The specificity of growth factor action is mediated by the interaction of ligand with cognate receptors resulting in the triggering of a defined biochemical pathway. Ultimately, a mitogenic or differentiation signal is delivered to the nucleus, completing the biological action of the growth factor. As growth factors play important roles in both normal and abnormal biology, defining the role of these cytokines in specific disease processes will help us towards greater understanding of the pathophysiologi cal process as well as provide us with new opportunities for diagnostic and therapeutic strategies for the treatment of the disease, e.g. urothelial proliferation disorders in spinal cord injury patients.
The Epidermal Growth Factor (EGF) belongs to a rapidly expanding family of peptide mitogens. 2 The kidney is postulated to be the source of urinary EGF, which is excreted in urine in high concentrations in a biologically active form. . Again cytoplasmic/membrane localisa tion in these studies was difficult to evaluate and no conclusion is presented. Epidermal Growth Factor is excreted in the urine in very high concentration in a biologically active form and this would suggest that in addition to a functional EGFR-p in vesical the urothelium of SCI patients D van Velzen et al role, even functionally activating basement membrane transgressing, epithelium anchoring cell processes, there may be functional EGF-Receptors in higher layers. Thus, depending on the permeability of the superficial lining, there may be an opportunity to react with cells of the bladder epithelium on a continual basis. In experimental models this is substantiated as a 45 to 60 minute exposure of the moderately distended rat bladder to intravesical EGF, stimulated dose related intramural induction of ornithine decarboxy lase activity and DNA synthesis in the basal urothelial cell layer. 4 However, in order to respond to EGF, cells must have functional, cell surface located receptors which allow for specific binding.
Vesical urothelial proliferation has been demon strated in some spinal cord injury patients. 5 A strategy aimed at optimizing urothelial proliferation in order to normalize differentiation-dependent surface character istics possibly influencing the propensity for patholo gical bacterial colonisation, may consider the use of EGF or EGF-like growth factor by intravesical instillation. Success for this strategy would require the continued expression of sufficient amounts of functional EGF receptors on the cell surface of the bladder urothelium, although expression on superficial cells, in the light of experimental and physiological data is probably not required. It is possible that the Table 1 Resume of clinical details of 18 patients in whom the urinary bladder trigone biopsies were studied by immunohistochemical staining for epidermal growth factor receptor in the urothelium Further, the malignant potential of the urothelium in the neuropathic bladder following spinal cord injury is well recognised, especially 15 to 20 years after spinal cord trauma. The incidence of vesical malignancy in the spinal cord injury population has been reported to be 2.3%. 9 Tumours in these patients are 460 times more common than are urinary bladder tumours in the general population. 9 The increased occurrence of bladder tumours correlates with the duration of urothelial inflammation, chronic urinary tract infec tions, vesical stone formation and indwelling catheter drainage of the urinary bladder. EGFR is highly expressed on malignant bladder cancer cells. Apart from conventional therapy for vesical neoplasia, molecular biological approaches are being developed in the laboratory for the possible treatment of neoplasia. The observation that anti-receptor anti bodies could revert the malignant phenotype of neu and c-neu/EGFR transformed cells in vitro and in vivo has been widely reproduced and represents a logical approach to specific anti-tumour thera�y which has now been taken to clinical application. I Monoclonal antibodies (MAbs) against four distinct epitopes on the external domain of the EGF receptor were found to inhibit the binding of Transforming Growth Factor and Epidermal Growth Factor to the receptor on tumour cells and these MAbs were able to inhibit the growth in vitro and in vivo of tumour cells that over-express the EGF receptor. I I Substances that selectively interfere with Epidermal Growth Factor Receptor tyrosine kinase have potential for the therapy of bladder cancer. 12 Potent tyrosine kinase inhibitors of the EGFR kinase arrest the growth of cells that over-express EGFR and inhibit tumours that over-express EGFR. 13 Systemic administration of keratinocyte growth factor, also known as FGF-7, which belongs to the fibroblast growth factor family of cytokines in a dose of 5 mg/kg resulted in rapid and striking proliferation of vesical urothelium in rats and rhesus monkeys. 1 4 Such a fundamental approach to modulation of urothelial proliferation is being con sidered for SCI patients, as drugs directed against the fundamental molecular mechanisms responsible for a specific pathology are nearly always more effective and less toxic than agents that merely treat the con sequences of a pathological process. IS As more information on the factual distribution of EGFR in the urothelium of SCI patients was required before any treatment strategy could be considered, we investigated the EGFR expression and localization in vesical urothelium of consecutive unselected spinal cord injury patients.
Patients and methods

Study population
Eighteen adult spinal cord injury patients who were otherwise scheduled for a therapeutic procedure such as division of the external urethral sphincter and transurethral resection of the bladder neck (n = 5), electrohydraulic lithotripsy of vesical stone(s) (n = 4), suprapubic cystolithotomy (n = 2), suprapubic cystost omy (n = I), JJ stent insertion (n = I), removal of JJ stent (n = I), ureterorenoscopy (n = I), attempted insertion of ureteric stent (n = I) or, diagnostic cystoscopy for evaluation of haematuria (n = 2) were the subjects of this study. The details of the proposed investigation (bladder biopsy) were discussed with the patient and his/her carer(s) and written informed consent was obtained from all of the patients. A cold-cup biopsy was taken under vision from the normal-looking bladder mucosa from the trigone of the urinary bladder. Any bleeding point was then fulgurated with diathermy electrode. Performance of bladder biospy did not result in any additional morbidity in these eighteen patients.
Biopsy procedure, tissue sampling Cold-cup biopsies were either fixed in 0.1 M, phosphate buffered, 4% formaldehyde, pH 7.4 for 6-24 h for routine histopathological analysis or snap frozen in liquid nitrogen and subsequently stored at -80C for immunohistochemical analysis of EGFR-protein dis tribution.
EGFR analysis, immunocytochemistry
Five micron frozen sections were cut at -24°C by Cryotome, mounted on coated slides and used for analysis with a commercially available, affinity purified monoclonal mouse anti-human epidermal growth factor receptor antibody (DAKO-EGF-Receptor, EGFRI, code no. M 886, Lot 101). DAKO EGF Receptor, EGFRI (DAKO, A/S, Produktionsvej 42, DK-2600 Glostrup, Denmark) reacts with the external domain of the epidermal growth factor receptor (MW 170 kD). Demonstration of binding used alkaline phosphatase and alpha-naphthol chromagen. The intensity of immunostaining was graded semiquantita tively for each patient on a six point scale ranging from negative, questionable (+ / -), mildly to very strongly positive on the remaining four points of the grading system (+ to + + + +). 
Analysis
The slides were read twice, blind, in randomised order, and patients biopsied. Five randomly chosen sites per biopsy were assessed. Histopathology of the bladder mucosal biopsy from the trigone, and immunohisto chemical observations on EGFR-p immunostaining viz (1) intensity of immunostaining as graded semiquanti tatively on a six point scale, (2) location of EGFR-p positivity in urothelial cell layers, (3) sub-basement membrane expression of EGFR-p, and (4) type of expression of EGFR-p (whether cytoplasmic or, cell membrane or, both cytoplasmic and cell membrane positive immunostaining), were recorded for each patient.
Results
Of the 18 SCI patients in whom bladder biopsy was taken, nine were on indwelling urethral catheter drainage; five were on penile condom drainage; two were performing intermittent catheterisation; one was on suprapubic drainage and one woman was using pads with reflex voiding (Table 1) . Histopathology of the bladder biospy revealed denuding cystitis in one; follicular cystitis in four; active inflammatory infiltrate in three (in a tetraplegic patient on indwelling catheter drainage, there was dense inflammatory infiltrate with granulation tissue development in the submucosa); lymphocytic infiltrate in three; squamous metaplasia in six; and intestinal metaplasia in three biopsy specimens (Table 2) . A linear localization of epidermal growth factor receptor along the cell membrane of the urothelium was observed in three cases (Figure 1 ). Cytoplasmic immunostaining of epidermal growth factor receptor was noted in 13 cases (Figure 2 ). Both cytoplasmic and cell membrane immunostaining were seen in two cases ( Figure 3) . In one patient, small aggregates of cells at mid-epithelial height showed strong cytoplasmic positivity of EGFR-p (stored?) separated from the basement membrane by 2 -3 layers of negative urothelial cells (Figure 4 ). The three cases with membrane immunostaining showed strong expres sion of EGFR (2 + , 2-3 + , and 4 + respectively). The intensity of EGFR expression varied in cases of cytoplasmic immunostaining: 2 + intensity in six cases; 1 -2 + intensity in one; 1 + staining in five cases; and + / -immunostaining in one patient. Presence of EGFR-p antigen in sub-basement membrane location, presumably on transmembranous cell protrusions, was not unequivocally recognised in patients with cytoplas mic expression, and only considered to be present in those cases with cell membrane localisation.
The three specimens showing cell membrane location of EGFR-p were from patients who did not have an indwelling urethral catheter (a paraplegic man practising intermittent self-catheterisation, a tetraple gic patient on penile condom drainage, and a tetraplegic woman with reflex voiding), and histo pathology of bladder biopsy revealed a uniform picture of a limited or very little inflammatory infiltrate with especially no evidence of invasion of the urothelium by inflammatory cells. In contrast, the biopsies from all the nine patients, who were on indwelling urethral catheter drainage, showed only cytoplasmic immunostaining of EGFR-p was observed in the vesical urothelium of all the six cases, albeit cell membrane localisation of EGFR-p was seen in the squamous metaplastic region of the biopsy in one patient (BC). The histopathology of trigone biopsy in these patients with vesical calculus showed denuding cystitis in one case, squamous metaplasia in two, intestinal metaplasia in one, follicular cystitis in one, and no inflammatory infiltrate in a patient who was practising intermittent self-catheterisation.
Discussion lmmunohistochemically, there may be membranous, cytoplasmic, or nuclear immunolocalization. 16 The latter type was not encountered in the present study. The type of fixation and tissue processing, as well as speed of fixation, may affect the intensity and localization of immunostaining. 16 All 18 bladder trigone biopsy specimens of the present study were fixed and processed in a uniform manner (immediate Liquid Nitrogen and subsequent storage at -80°C prior to cryo-sectioning at -24°C) thus ruling out both variability and insufficiency due to deficienciesj differences in fixation or processing techniques. Thus the absence of nuclear location of EGFR-protein antigen presence, at least over the detection levels of the technique used, in these human tissues is to be accepted. The normal pattern of (detectable) expression of EGFR-p is on the cell membrane. In this study, this was found as the sole mode of expression in three patients. In two patients cell membrane presence was combined with cytoplasmic expression: in one patient in side-by-side; in one patient by the presence of both distributions within single cells. Stimulation of the normally located, i.e. functional epidermal growth factor receptor induces tyrosine kinase activity and cellular signalling that results in cell growth and proliferation. 17 When single immunohistochemical staining for EGF-R was performed in regenerating liver nodules, the hepatocytes showed linear staining along the cell membrane. IS In the present study, immunohistochemical localization of EGFR-p was performed on 18 bladder mucosal biopsies from the trigone and in 13 of them, only cytoplasmic immunostaining of EGFR-p was observed with absent cell membrane expression. Decline in cell surface expression of the epidermal growth factor receptor is associated with diminished responsiveness to epidermal growth factor. 19 As all the nine SCI patients with indwelling urethral catheter drainage showed only cytoplasmic location of EGFR-p, the potential for intravesical administration of EGFR as a treatment modality may be limited.
Thirteen patients showed unequivocal cytoplasmic presence of EGFR-p antigen. Decrease in cytoplasmic staining of EGFR may reflect either a defect of internalization from the plasma membrane, decreased synthesis, increased degradation andjor distribution to another cell compartment (nucleus). Indeed, there is circumstantial evidence that all three could be involved in the phenomena of decreased cytoplasmic EG F receptor content. 20 In contrast, we observed cytoplas mic localisation of EGFR-p in the absence of cell membrane immunostaining in 13 of the 18 patients with SCI. In these cases this may be interpreted as representing a raised level of cytoplasmic EGFR-p presence. With reference to the explanations offered for a reduction, such an increase may then be explained by any or all of the same, but reversed, factors. As under normal circumstances a negative feed back effect on EGFR-p synthesis may be expected to result from successful incorporation of the protein into the cell membrane, excess cytoplasmic antigen presence may be interpreted as resulting from the absence of negative feed back effects. This may result from a defect in post-synthesis transport mechanisms or from a primary abnormality of the protein structure which precludes either transport or normal integration into the cell membrane. Should the latter be the case, failure of EGFR to localize the cell membrane may mean the absence of EGFR sequences necessary for appropriate cell membrane localization. It is known that human EGFRs truncated at Arg-651 were localized predominantly at the apical surface of filter-grown cells, whereas receptors truncated at Leu-723 were located predominantly basolateral, thus suggesting that the gene controlling the synthesis of the finalised receptors also contains complex structural information that results in a positive basolateral sorting determinant. 21 Such a complex would theore tically be more vulnerable to random disruptions. Alternatively, abnormalities in the urothelial mucosa innervation may result in defective normal gradient of nervous system derived soluble factors. If this gradient is required for the final structuring as described by Hobert and Carlin, 21 then the resultant increase of cytoplasmic EGFR-p may represent incomplete synth esis rather than a primary defective product which cannot be integrated precluding negative feed back restriction of the (first steps of the) synthesis process. Thus a detailed study of the relationship between abnormalities of EGFR-p distribution and urothelial nerve fibre abnormalities in patients with SCI is warranted and required.
Cytoplasmic localization of c-erbB-2 product p 185 in human mammary carcinoma was associated with low proliferating tumour cell fraction. 22 Thus cyto plasmic localization of EGRF-p with absent cell surface expression in vesical urothelium of SCI patients may be a significant observation in the light of the fact that vesical urothelial proliferation arrest has been reported in SCI patients. 5 Further, there is evidence suggesting colocaliza tion and correlations in the expression of EGFR and the cell-cell adhesion molecule E-cadherin. Immunolocalization of E-cadher in was enhanced in cell lines expressing functional or hyperfunctional EG FR, compared to cell lines expressing non-functioning mutant EGFR, or no EGFR at all. 23 Thus alterations in the expression of EGFR in SCI patients, as observed in the present study, may in turn result in changes in E-cadherin expression (as EGFR activation may regulate or enhance E-cadherin expression) and may either lead to increased cell-cell adhesion or disruption of cell-cell adhesion. SCI patients with reduced expression of EGFR or those expressing non-functional EGFR (non-functioning mutant EGFR, or no functional EGFR per se), may become prone to develop cystitis partly due to changes in E-cadherin expression since E-cadherin may play an important role in bacterial adhesion on the urothelial cells and thus may contribute to abnormal bacterial colonisation of neuropathic bladder. Indeed, some SCI patients suffer from frequent episodes of cystitis in the absence of any other apparent predisposing factor(s) for the develop ment of urinary tract infection, e.g. blocked catheter in those with indwelling urethral catheter drainage, or over-distension of the urinary bladder in the SCI patients who were practising intermittent catheterisa tion, or retention of large amounts of urine in those with penile condom drainage, vesical stone(s), etc. Immunohistochemical studies of (I) EGFR expression on vesical urothelium and (2) proliferating cell nuclear antigen and Ki-67 in these SCI patients who develop recurrent episodes of cystitis may provide insight to the urothelial proliferation disorders in the neuro pathic bladder which probably contribute to their susceptibility for development of frequent episodes of urinary infections and help to monitor their response to possible use of growth factors to optimise urothelial proliferation.
In future studies, absolute quantification of the amount of EGFR-p/urothelial cells will be of use. Quantification of epidermal growth factor receptors in this study was made by grading the intensity of immunostaining semiquantitatively as there is more antigen present in cells that stain strongly than in cc\ls that stain weakly. 16 However, understandably, this method gives only a limited and approximate assessment of the number of EGF receptors on single cells. Confocal laser scanning microscopy is a powerful tool for detecting EGFR on single cells. Using EGF biotin as the ligand to bind the EGF receptor in combination with a fluorescent secondary antibody, Good and associates 24 demonstrated that confocal laser scanning microscopy is able to quantify EGF receptor numbers on individual cells, with a lower limit below 10 000 receptors/cell. In addition to allowing quantification of the binding, confocal laser scanning microscopy is also equipped to study growth factor receptor localization, either by applying three dimensional visualization through stereo images, or by making optical sections. Thus a longitudinal study of the localization and quantification of epidermal growth factor receptors on single urothelial cells by confocal laser scanning microscopy in SCI patients in a sequential manner, preferably annually after spinal cord trauma, and correlation of these findings with the EGFR-p in vesical the urothelium of SCI patients D van Velzen et at clinical observations of urinary tract infections as well as histological changes of urothelial inflammation of urinary tract infections as well as histological changes of urothelial inflammation, atrophy, and metaplasia/ dysplasia or neoplasia, should it occur, will contribute to better understanding of the altered urinary bladder physiology in SCI patients and in turn, provide the scientific rationale for innovative treatment strategies for the inappropriate expression of EGFR in the vesical urothelium of SCI patients.
